Drug developer Novavax Inc. on Tuesday said the Centers for Disease Control and Prevention agreed to test the company's bird flu vaccine against a live strain of the H5N1 virus that causes the disease.

Under the agreement, Novavax will provide the CDC with a year's supply of its virus-like particle, or VLP, H5N1 vaccine. Novavax also plans to begin human testing of the vaccine in the first half of 2007.

VLPs are structures that are identical to a virus but lack the genetic material required to replicate, allowing for the body to produce an immune response without risking an infection.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP